nejm tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide outperforms semaglutide in NEJM

AGA and telogen effluvium can have overlapping symptoms, but they differ in several key areas: Onset: Telogen effluvium is a sudden increase in shedding occurring approximately 2-3 months after a trigger (such as starting Ozempic), whereas AGA occurs gradually over years

At the start of the study, people typically weighed more than 16st (104.8kg) and had a BMI of 38

The benefits extend beyond patients, as prescribers can manage medication requests more efficiently, leading to improved patient care and reduced delays in treatment

Retatrutide: follow what is known about Lilly's investigational triple agonist and why it is not a prescription option